Pimecrolimus for psoriasis

Bibliography

• Michelle EA, de Jager M, Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol 2010;62(6):1013-30
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;7:370-263
   Google Scholar
• Ali A, Raddadi Al, Mohammad IF, Adopted guidelines of care for the topical management of psoriasis from American and German guidelines. J Saudi Society Dermatol Dermatol Surge 2011;15:5-13
   Google Scholar
• Coimbra S, Figueiredo A, Castro E, The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol 2012;51(4):389-95
   PubMed Web of Science ®Google Scholar
• de Kerkhof V. editor. Textbook of psoriasis. 2nd edition. Blackwell, Oxford; 2003
   Google Scholar
• Laws PM, Young HS. Topical treatment of psoriasis. Expert Opin Pharmacother 2010;11(12):1999-2009
   PubMed Web of Science ®Google Scholar
• Halverstam CP, Lebwohl M. Nonstandard and off-label therapies for psoriasis. Clin Dermatol 2008;26(5):546-53
   PubMed Web of Science ®Google Scholar
• Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother 2004;5(3):643-55
   PubMed Web of Science ®Google Scholar
• Kapp A, Allen BR, Reitamo S. Atopic dermatitis management with tacrolimus ointment (Protopic). J Dermatol Treat 2003;14(Suppl 1):5-16
   PubMedGoogle Scholar
• Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs 2005;65:827-58
   PubMed Web of Science ®Google Scholar
• Wellington K, Jarvis B. Topical pimecrolimus. A review of its clinical potential in the management of atopic dermatitis. Drugs 2002;62:817-40
   PubMed Web of Science ®Google Scholar
• Graham-Brown RAC, Grassberger M. Pimecrolimus: a review of pre-clinical and clinical data. Int J Clin Pract 2003;57:319-27
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1% – a non-steroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 2003;111:1153-65
   PubMed Web of Science ®Google Scholar
• Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus – an anti-inflammatory drug targeting the skin. Exp Dermatol 2004;31:721-3
   Google Scholar
• Billich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through the skin than corticosteroids and tacrolimus. Int J Pharm 2004;269:29-35
   PubMed Web of Science ®Google Scholar
• Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005;211:174-87
   PubMed Web of Science ®Google Scholar
• Bos JD. Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis. Eur J Dermatol 2003;13:455-61
   PubMed Web of Science ®Google Scholar
• Alomar A, Berth-Jones J, Bos JD, (European Working Group on Atopic Dermatitis): The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004;151(Suppl 70):3-27
   PubMed Web of Science ®Google Scholar
• Ring J, Alomar A, Bieber T, Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 2012;26(9):1176-93
   PubMed Web of Science ®Google Scholar
• Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981)–preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001;20(4):233-41
   PubMed Web of Science ®Google Scholar
• Harper J, Green A, Scott G, First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001;144:781-7
   PubMed Web of Science ®Google Scholar
• Van Leent EJ, Ebelin ME, Burtin P, Low systemic exposure after repeated topical application of Pimecrolimus (Elidel, SD Z ASM 981) in patients with atopic dermatitis. Dermatology 2002;204(1):63-8
   PubMed Web of Science ®Google Scholar
• Lakhanpaul M, Davies T, Allen BR, Schneider D. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%. Exp Dermatol 2006;15(2):138-41
   PubMed Web of Science ®Google Scholar
• Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 2012;66(3):369-75
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978;157(4):238-44
   PubMedGoogle Scholar
• Menter A, Korman NJ, Feldman SR, Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58(5):826-50
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof PC, Barker J, Griffiths CE, Psoriasis: consensus on topical therapies. J Eur Acad Dermatol Venereol 2008;22(7):859-70
   PubMed Web of Science ®Google Scholar
• Korfitis C, Gregoriou S, Rallis E, Rigopoulos D. Pimecrolimus versus topical corticosteroids in dermatology. Expert Opin Pharmacother 2007;8(10):1565-73
   PubMed Web of Science ®Google Scholar
• Gupta AK, Chow M. Pimecrolimus: a Review. JEADV 2003;17:493-503
   Google Scholar
• Ashcroft DM, Dimmock P, Garside R, Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005;330(7490):516
   PubMed Web of Science ®Google Scholar
• Wollina U, Hansel G, Koch A, Abdel-Naser MB. Topical pimecrolimus for skin disease other than atopic dermatitis. Expert Opin Pharmacother 2006;7(14):1967-75
   PubMed Web of Science ®Google Scholar
• Van Leent EJM, Graber M, Thurston M, Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998;134:804-9
   PubMedGoogle Scholar
• Luger T, Van Leent EJM, Graeber M, SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144:788-94
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Wustlich S, Hoexter G, Pimecrolimus (SDZ ASM 981) ointment is effective in psoriasis without occlusion. Acta Derm Venereol 2003;3(5):351-3
   Google Scholar
• Bigby M. Pimecrolimus and tacrolimus for the treatment of intertriginous and facial psoriasis: are they effective? Arch Dermatol 2005;141(9):1152-3
   PubMedGoogle Scholar
• Paul C, Graeber M, Stuetz A, Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Investig Drugs 2000;9:69-77
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Graeber M, Brautigam M, The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998;139(6):992-6
   PubMed Web of Science ®Google Scholar
• Remitz A, Reitamo S, Erkko P, Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999;141:103-7
   PubMed Web of Science ®Google Scholar
• Gribetz C, Ling M, Lebwohl M, Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004;51:731-8
   PubMed Web of Science ®Google Scholar
• Kreuter A, Sommer A, Hyun J, 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006;142:1138-43
   PubMedGoogle Scholar
• Lebwohl M, Freeman AK, Chapman MS, Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004;51:723-30
   PubMed Web of Science ®Google Scholar
• Ring J, Mohrenschlager M, Henkel V. The US FDA ‘black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 2008;31(3):185-98
   PubMed Web of Science ®Google Scholar
• Berger TG, Duvic M, Van Voorhees AS, The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006;54:818-23
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60:643-59
   PubMed Web of Science ®Google Scholar
• Rappersberger K, Komar M, Ebelin ME, Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis, and is well tolerated. J Invest Dermatol 2002;119:876-87
   PubMed Web of Science ®Google Scholar
• Paul C, Ho VC. Ascomycins in dermatology. Semin Cutan Med Surg 1998;17:256-9
   PubMed Web of Science ®Google Scholar
• Crawford KM, Russ B, Bostrom P. Pimecrolimus for treatment of acne rosacea. Skinmed 2005;4(3):147-50
   PubMedGoogle Scholar
• Chu CY. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol 2005;152:396-9
   PubMed Web of Science ®Google Scholar
• Zabawski E. Treatment of cutaneous lupus with Elidel TM. Dermatology Online J 2002;8:25
   PubMedGoogle Scholar
• Tlacuilo-Parra A, Guevara-Gutirrez E, Gutirrez-Murillo F, Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology 2005;44:1564-8
   PubMed Web of Science ®Google Scholar
• Kreuter A, Gambichler T, Breuckmann F, Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004;51:407-10
   PubMed Web of Science ®Google Scholar
• Lim SJ, Love EW. Steroid-free pimecrolimus (Elidel) for monotherapy of lichen planus. J Drugs Dermatol 2004;3:563-4
   PubMedGoogle Scholar
• Gottlieb AB, Griffiths CEM, Ho VC, Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol 2005;152(6):1219-27
   PubMed Web of Science ®Google Scholar
• Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun in patients with severe psoriasis. OLP302 Study Group. Br J Dermatol 1998;139(1):88-95
   PubMed Web of Science ®Google Scholar
• Heydendael VM, Spuls PI, Opmeer BC, Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349(7):658-65
   PubMed Web of Science ®Google Scholar
• Garside R, Stein K, Castelnuovo E, The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. Health Technol Assess 2005;9(29): iii, xi-xiii, 1-230
   Web of Science ®Google Scholar
• Frankel HC, Qureshi AA. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis. Am J Clin Dermatol 2012;13(2):113-23
   PubMed Web of Science ®Google Scholar
• Lehmmann P, Ruzicka T. Topical calcipotriol in the treatment of intertriginous psoriasis. Br J Dermatol 1996;135:647-50
   PubMed Web of Science ®Google Scholar
• Jacobi A, Braeutigam M, Mahler V, Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. Dermatology 2008;216(2):133-6
   PubMed Web of Science ®Google Scholar
• Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol 2007;8:143-55
   PubMed Web of Science ®Google Scholar
• Griffiths C. Commentary: biologics for psoriasis: steps to heaven 17. Br J Dermatol 2012;167(4):715-16
   PubMed Web of Science ®Google Scholar
• Papoutsaki M, Talamonti M, Giunta A, The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology 2010;221(Suppl 1):43-7
   PubMed Web of Science ®Google Scholar
• Gordon K, Papp K, Poulin Y, Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2011;66:241-51
   Google Scholar
• Kimball A, Goffe B, Bissonnette R, Efficacy of ustekinumab is sustained through 3 years of treatment for patients with moderatesevere psoriasis on Q12 week dosing based on body weight. Poster presented at PSO 2010, in Congress of the Psoriasis International Network; Paris; 2010
   Google Scholar
• NICE. TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: guidance; 2004
   Google Scholar